Transdiagnostic inflammatory subgroups among psychiatric disorders and their relevance to role functioning: a nested case-control study of the ALSPAC cohort

Jonah F. Byrne1,2✉, Colm Healy1, David Mongan1,3, Subash Raj Susai1, Stan Zammit4,5, Melanie Föcking6,7, Mary Cannon1,2 and David R. Cotter1,2

Individuals with psychotic disorders and depressive disorder exhibit altered concentrations of peripheral inflammatory markers. It has been suggested that clinical trials of anti-inflammatory therapies for psychiatric disorders should stratify patients by their inflammatory profile. Hence, we investigated whether different subgroups of individuals exist across psychiatric disorders, based on their inflammatory biomarker signatures. We measured the plasma concentrations of 17 inflammatory markers and receptors in 380 participants with psychotic disorder, depressive disorder or generalised anxiety disorder and 399 controls without psychiatric symptoms from the ALSPAC cohort at age 24. We employed a semi-supervised clustering algorithm, which discriminates multiple clusters of psychiatric disorder cases from controls. The best fit was for a two-cluster model of participants with psychiatric disorders (Adjusted Rand Index (ARI) = 0.52 ± 0.01) based on the inflammatory markers. Permutation analysis indicated the stability of the clustering solution performed better than chance (ARI = 0.43 ± 0.11; p < 0.001), and the clusters explained the inflammatory marker data better than a Gaussian distribution (p = 0.021). Cluster 2 exhibited marked increases in sTNFR1/2, suPAR, sCD93 and sIL-2RA, compared to cluster 1. Participants in the cluster exhibiting higher inflammation were less likely to be in employment, education or training, indicating poorer role functioning. This study found evidence for a novel pattern of inflammatory markers specific to psychiatric disorders and strongly associated with a transdiagnostic measure of illness severity. sTNFR1/2, suPAR, sCD93 and sIL-2RA could be used to stratify clinical trials of anti-inflammatory therapies for psychiatric disorders.

Translational Psychiatry (2022)12:377 ; https://doi.org/10.1038/s41398-022-02142-2

INTRODUCTION
Depressive disorder, first-episode psychosis (FEP), and generalised anxiety disorder have been associated with increased pro-inflammatory markers such as interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α) or C-reactive protein (CRP) [1–5]. Several clinical trials of adjunctive anti-inflammatory therapies for psychotic disorders and depressive disorder have been conducted showing modest effect sizes [6–8]. There have been calls for future trials to stratify patients by their immune profile [6, 9] and for therapies to be guided by the understanding of transdiagnostic neurobiological mechanisms [10, 11].

Previous meta-analyses have assessed the variability of inflammatory markers in individuals with depression [12] and FEP [13] compared to controls. These studies found that the variability of IL-6, IL-8, IL-10, CRP, TNF-α and interferon-gamma (IFN-γ) is not higher in patients than controls. Indeed, there is evidence that CRP levels show less variability in individuals with depression [12] and that IL-6, IL-8 and TNF-α levels show less variability in individuals with psychotic disorders [13]. Less or equal variability of inflammatory markers in patients compared to controls does not support the hypothesis that inflammatory subgroups of psychotic disorder or depression exist, at least on the basis of individual markers.

Previous studies that have identified inflammatory subgroups based on multiple inflammatory markers have derived clusters containing both individuals with psychiatric disorders and controls [14–16], or have identified subgroups of individuals with depression or schizophrenia without direct inclusion of controls in the analysis [17–20]. In some cases, uncertainty remains as to whether identified clusters could also be found in a non-psychiatric population, thus potentially representing inflammatory processes that are not relevant to mental illness.

In this study, we aimed to investigate the existence of transdiagnostic inflammatory subgroups with specific relevance to psychiatric disorders, and to characterise such subgroups. Taking a data-driven approach, we applied a semi-supervised clustering method [21] that derives clusters of individuals with psychiatric disorders based on their differences from controls. Furthermore, the method allows for covariate adjustment and internal validation to estimate the stability of the clusters. In our analysis we included

1Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland. 2SFI FutureNeuro Research Centre, Royal College of Surgeons in Ireland, Dublin, Ireland. 3Centre for Public Health, Queen’s University Belfast, Belfast, UK. 4Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. 5Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK. 
电子邮件: jonahbyrne21@rcsi.ie

Received: 4 April 2022 Revised: 22 August 2022 Accepted: 25 August 2022
Published online: 09 September 2022
several cytokines, cytokine receptors and cellular adhesion molecules, as well as a putative biomarker of chronic inflammation; soluble urokinase plasminogen activation receptor [22, 23], and the complement-related inflammatory regulators: alpha-2-macroglobulin [24] and cluster of differentiation 93 (CD93) [25].

SUBJECTS AND METHODS
Participants and study design
The Avon Longitudinal Study of Parents and Children (ALSPAC) study is a prospective general population cohort [26–28]. Pregnant women in Avon, United Kingdom, with delivery dates between April 1, 1991, and December 31, 1992, were invited to participate, and 14,541 pregnancies were enrolled. When the children were approximately 7 years old, an attempt was made to bolster the initial sample with children who did not join originally. The study sample size at age 7 is 15,454 pregnancies of whom 14,901 children were alive at 1 year of age. Study data were collected and managed using REDCap electronic data capture tools [29]. The study website contains details of all data that are available through a fully searchable data dictionary and variable search tool (http://www.bristol.ac.uk/alspac/researchers/our-data).

Participants were invited to attend a clinic when they were approximately 24 years old. 4019 (40.4% of those invited) attended this clinic, where anthropometric measurements, questionnaires, and interviews were completed and blood samples were collected. This study is based on a subsample (n = 779) of individuals who attended this clinic.

Cases were defined as those meeting the criteria for diagnosis of either psychotic disorder, moderate/severe depressive disorder, or generalised anxiety disorder (n = 380) at age 24 years, as assessed by the Psychosis-Like Symptoms Interview [30, 31] or the revised Clinical Interview Schedule (CIS-R) [32]. All participants who met these criteria and concurrently provided consent for a plasma sample to be taken were included. Controls were defined as not meeting criteria for any of the above disorders (including mild depressive disorder) and not having suspected or definite psychotic experiences within the past year. Controls were sampled from participants who attended clinics at age 11, 17, and 24 and had data available for BMI (n = 399).

Clinical measures
Psychiatric outcomes were defined as described previously [33].

Psychotic disorder and psychotic experiences. Participants completed the semi-structured Psychosis-Like Symptoms Interview (PLIKSi) to assess for psychotic symptoms [30, 31]. Trained interviewers assessed participants for psychotic experiences, including hallucinations, delusions, and experiences of thought interference. Psychotic experiences within the past year were rated by interviewers as not present, suspected or definitely present. Responses were coded according to the Schedules of Clinical Assessment in Neuropsychiatry [34]. As in previous studies [31, 35], psychotic disorder was defined as having at least one definite psychotic experience not attributable to sleep or fever, which recurred at least once per month over the previous six months, and was associated with severe distress, marked impairment of the participant’s social or occupational functioning, or led them to seek help.

Depressive disorder and generalised anxiety disorder. Participants completed the self-administered computerised version of the CIS-R [32]. In the CIS-R, the severity, frequency, and persistence of symptoms are assessed to derive diagnoses of depressive disorder (mild, moderate, or severe) and generalised anxiety disorder according to the International Classification of Diseases version 10 [36].

Clinical characteristics. As part of the CIS-R, participants reported on the presence of anhedonia and sleep problems. As part of the same clinic, participants reported if they were daily smokers, if they had any major physical health conditions, and whether they were not in employment, education or training (NEET; neither part-time nor full-time). Major physical health conditions included arthritis, diabetes, stroke, cancer, heart disease or heart problems. Data on medication use for hallucinations/delusions or other mental health problem were collected as part of the PLIKSi.

Inflammatory biomarker measurements
Blood samples were collected and processed according to a standardised protocol. Plasma inflammatory biomarkers were measured using enzyme-linked immunoassorbent assays (ELISA) and proximity extension assays (PEA) blind to case/control status. Samples were randomised according to a random sequence prior to biomarker measurements. Further details on sample collection and biomarker measurements can be found in the Supplementary methods.

Multiplex ELISA analyses. Plasma concentrations of IFN-γ, TNF-α, interleukin-1-beta (IL-1-β), IL-2, IL-4, IL-6, IL-8, IL-10, IL-13, CRP, soluble intracellular adhesion molecule-1 (ICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were measured using the multiplex V-Plex Pro-Inflammatory Panel 1 (Meso Scale Diagnostics (MSD; Maryland, USA), K15049D) and V-Plex Vascular Injury Panel 2 (MSD, K15198D) according to manufacturer’s instructions. Standards and samples were run in duplicate and the mean value for each duplicate pair was used in analyses. The lower limits of detection for each marker can be found in Supplementary Table 1.

Soluble urokinase plasminogen activation receptor (suPAR). Plasma concentrations of suPAR were measured using the suPARnostic ELISA kit (Virotek, Birkered, Denmark, https://www.virotek.com/suparnostic-elisa/) according to the manufacturer’s instructions. Standards were run in duplicate and in singlet. The lower limit of detection for this assay is 0.4 ng/ml.

Alpha-2-macroglobulin (A2M). Plasma concentrations of A2M were measured using human alpha-2-macroglobulin ELISA kit (Abcam; Cambridge, UK; ab108888) according to manufacturer’s instructions. Standards were run in duplicate and in singlet. The lower limit of detection for this assay is 0.05 µg/ml.

Inflammatory biomarker receptors. Plasma concentrations of circulating tumour necrosis factor receptor 1 (TNFFR1), tumour necrosis factor receptor 2 (TNFFR2), interleukin-1 receptor type 1 (IL-1RT1), interleukin-1 receptor type 2 (IL-1RT2), interleukin-2 receptor subunit alpha (IL-2RA), interleukin-6 receptor subunit alpha (IL-6RA) and CD93 were measured using a commercially available PEA, Cardiovascular Panel III (Olink Proteomics; Uppsala, Sweden; https://www.olink.com). Samples were run in singlet. The lower limits of detection for each marker measured by PEA can be found in Supplementary Table 1.

The 7 receptors were chosen a priori from the 92 proteins available on the Cardiovascular Panel III. We hypothesised that the interactions between cytokines and cytokine receptors would be particularly informative. Referring to previous literature, we included cytokine receptors where the related cytokine was shown to have meta-analytical association with depression or psychotic disorders [1–4]. Due to previous evidence of the involvement of the complement system in psychosis [37–39], we included the complement-related protein CD93.

Data pre-processing
As a means of quality control, inflammatory markers measured with multiplex ELISA were included in the analyses if ≥80% of plasma concentration values were above the limit of detection and ≥80% of concentration values had a coefficient of variation (CV) of ≤20%. Separate quality control criteria for suPAR, A2M and markers measured with PEA required ≥80% of plasma concentration values to be above the limit of detection.

Values below the limit of detection for any marker were replaced with the corresponding lower limit of detection divided by the square root of 2. Plasma duplicate concentration values were log-transformed where the Fisher-Pearson coefficient of skewness for the distribution of each marker was greater than 1. All values were subsequently converted to z-scores and winorised within ±4 standard deviations to reduce the effects of outliers. Imputation was carried out using the K-Nearest Neighbours algorithm (KNN = 7). In total, 1.2% of all biomarker values were imputed, including values which were outside the range of the curve fit for each marker, values with a corresponding CV of >20% and values that were missing due to insufficient sample volume. The number of missing values for each marker is presented in Supplementary Table 2.

Subtyping
We applied the semi-supervised clustering algorithm HYDRA (heterogeneity through discriminant analysis) [21] to the inflammatory biomarker data of the participants to investigate the presence of stable, reproducible clusters. The algorithm HYDRA fits multiple linear classifiers, which each
 distinguish clusters of cases from controls for separate reasons. The number of clusters (K) being evaluated is directly linked to the number of linear classifiers used. Disorder clusters are thus identified by the shared characteristics that delineate them from controls. In this study, cases are individuals with psychiatric disorders, and the characteristics used to separate cases from controls are patterns of inflammatory marker levels.

The semi-supervised approach of HYDRA has advantages over other clustering methods: by using controls as a reference population, the algorithm clusters cases based on features relevant to the disorder of interest. Furthermore, it allows correction for covariates (in this case, sex and BMI), in attempt to capture heterogeneity related to the disorders and minimise confounding to the clustering solution.

As the clusters derived in this study differed in proportions of daily smokers, we investigated whether the clusters were confounded by smoking. We repeated our analysis adjusting for a binary variable of daily smokers, we investigated whether the clusters were confounded by smoking. We repeated our analysis adjusting for a binary variable of daily smokers (Yes/No) in addition to sex and BMI.

**Statistical analysis**

The significance of clustering solutions was assessed using the SigClust method [40, 41], with the null hypothesis that the data are from a single Gaussian distribution. The parameters for the null Gaussian distribution are estimated from the data, and the significance of clustering is then tested by simulation from this distribution. The “SigClust” package for R was run with 1000 simulations.

Additionally, a null distribution was derived by random permutation analysis, which indicated the stability of clustering solutions that could be found by chance (further details in Supplementary methods). Welch’s t-test for unequal variances was used to compare replications of the main analysis to the null distribution.

Currently, there are no guidelines for estimating the sample-size requirements for the clustering method implemented in this study. To reduce the risk of overfitting, we kept the number of events-per-variable above 20.

Differences in case and control characteristics or cluster characteristics were compared using the Wilcoxon–Mann–Whitney two-sample rank sum test (two-sided) or Pearson’s Chi-squared test. We chose to investigate differences in potential confounders between clusters (sex, BMI, smoking, sleep problems, major physical health conditions, medication use for mental health problems). Furthermore, we investigated differences in the major psychiatric symptoms; anhedonia and psychotic experiences, which have previously been associated with inflammatory markers [20, 42, 43] and differences in role functioning between clusters, as measured by NEET status. P-values were not adjusted for multiple comparisons.

Logistic regression models were used to investigate whether clinical characteristics were associated with cluster membership beyond certain confounders, using binary cluster membership as the dependent variable and the clinical characteristic as the independent variable. The analyses were conducted adjusting for sex, BMI, daily smoking and medication use for mental health problems. Using the same approach, logistic regression models were also used to investigate whether each inflammatory marker was associated with cluster membership beyond certain confounders. Analyses were conducted in R (4.1.0) and python (3.9).

**RESULTS**

**General descriptive statistics**

In our sample of psychiatric disorder cases, 40 participants (10.5% of cases) met criteria for psychotic disorder, 202 (53.1%) met criteria for moderate or severe depression and 268 (70.5%) met criteria for GAD at age 24 years. 113 (29.7% of cases) participants met criteria for more than one disorder. Participants who met the criteria for any of the three psychiatric disorders had a higher proportion of females (74.5%) than the control population (52.4%; p < 0.001) and had a higher mean BMI (25.4 kg/m²; 95% confidence interval [CI] 24.8–26.0 kg/m²) than controls (24.0 kg/m²; 95% CI 24.4–23.6 kg/m²; p = 0.018) (Table 1).

**Cluster analysis**

The markers IL-6, IL-8, IL-10, TNF-α, IFN-γ, CRP, sVCAM-1, sICAM-1, suPAR, A2M, IL-1RT1, IL-1RT2, IL-2RA, IL-6RA, TNFR1, TNFR2 and CD93 met quality control criteria and were included in the analysis. HYDRA was run with internal validation across 100 subsamples. The highest ARI (0.52; standard deviation (SD) = 0.01) was for a two-cluster solution of psychiatric disorder participants (Fig. 1). Simulation with the Sigclust method indicated that the clusters explained the data better than a Gaussian distribution (p = 0.021). Comparison with results from permutation analyses (ARI of 0.43 ± 0.11 for two clusters) indicated the stability of the clustering solution performed better than chance (p < 0.001).

The 95% CIs for differences in cluster inflammatory marker means indicated cluster 2 had broadly higher levels of inflammatory markers than cluster 1. The largest differences between the clusters were observed for the markers TNFR2, TNFR1, suPAR, CD93 and IL2RA (Fig. 2 and Table 2). Differences in inflammatory marker levels between each cluster and controls are presented in Supplementary Table 6. Cluster 2 had broadly higher levels of inflammatory markers than controls and cluster 1 had broadly lower levels of inflammatory markers than controls. Cluster 2 inflammatory marker levels were separated from controls more strongly than cluster 1 levels were separated from controls. The clusters differed in proportions of individuals who were daily smokers, had psychotic experiences within the past year and were not in employment, education or training (Table 3).
Logistic regression analyses demonstrated that the association between NEET status and cluster membership remained while adjusting for sex, BMI, daily smoking and medication use for mental health problems (odds ratio [OR] 2.80, 95% CI 1.50, 5.35). The association between psychotic experiences and cluster membership attenuated while adjusting for the same covariates (OR 1.80, 95% CI 0.99, 3.30).

**Sensitivity analyses**

To investigate whether the clustering solution was confounded by smoking, we conducted a sensitivity analysis where the algorithm HYDRA was run with daily smoker as an additional covariate. The highest ARI was for a two-cluster solution (mean = 0.50, SD = 0.01). The inflammatory marker distributions of the two clusters (Supplementary Fig. 2) were in agreement with our main analysis. Simulation with the Sigclust method indicated that the clusters explained the data better than a Gaussian distribution ($p = 0.039$). Comparison with results from permutation analyses (ARI of 0.41 ± 0.12 for two clusters) indicated the stability of the clustering solution performed better than chance ($p = 0.018$) while adjusting for smoking.

In addition, we conducted a sensitivity analysis where the algorithm HYDRA was run excluding individuals with a major physical health condition or BMI > 30. The highest ARI (0.50, SD = 0.02) was for a two-cluster solution. Simulation with the Sigclust method indicated that the clusters explained the data better than a Gaussian distribution ($p = 0.017$). The inflammatory marker distributions of the clusters obtained in this sensitivity analysis were in agreement with our main analysis (Supplementary Fig. 3).

**Fig. 1** The Adjusted Rand Index for $K$ clusters of the psychiatric disorder group compared to the null distribution obtained from random permutations. Data are represented as mean ±95% CI for each clustering solution between 2 and 5 clusters. The highest ARI was for a two-cluster solution of individuals with psychiatric disorders.

**Fig. 2** Distribution of standardised inflammatory biomarker values in each cluster as determined by semi-supervised clustering. A consensus clustering solution across 100 subsamples was determined by the algorithm HYDRA, adjusting for sex and BMI. Simulation with the Sigclust method indicated that the clusters explained the data better than a Gaussian distribution ($p = 0.021$). Interferon-gamma (IFN-$\gamma$), interleukin-10 (IL-10), interleukin-6 (IL-6), interleukin-8 (IL-8), tumour necrosis factor-alpha (TNF-$\alpha$), C-reactive protein (CRP), soluble intracellular adhesion molecule-1s (ICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble urokinase plasminogen activation receptor (suPAR), alpha-2-macroglobulin (A2M), tumour necrosis factor receptor 1 (TNFR1), tumour necrosis factor receptor 2 (TNFR2), interleukin-1 receptor type 1 (IL-1RT1), interleukin-1 receptor type 2 (IL-1RT2), interleukin-2 receptor subunit alpha (IL-2RA), interleukin-6 receptor subunit alpha (IL-6RA), cluster of differentiation 93 (CD93).
DISCUSSION

In a large population-based cohort, we investigated the existence of inflammatory subgroups using a transdiagnostic approach and data-driven, multivariable methods that had the potential to reveal inflammatory subgroups with specific relevance to psychiatric disorders.

Our analysis identified two subgroups with fair stability (ARI = 0.52 ± 0.01). Thus, we found evidence for inflammatory subgroups of psychiatric disorders. This is in contrast to evidence from previous meta-analyses which did not find that the variability of cytokines was greater in patients than in controls [12, 13]. These previous studies by Osimo et al. and Pillinger et al. investigated evidence for subgroups of depression [12] or FEP [13] alone based on individual inflammatory cytokines, while the current study assessed 17 inflammatory markers and searched for subgroups among 3 psychiatric disorders. Furthermore, the largest differences observed between the subgroups we identified were for levels of inflammatory marker receptors that could were not examined by Osimo et al. and Pillinger et al., rather than inflammatory markers such as IL-6 and CRP, which have been a primary focus of immunopsychiatry research.

Among the strongest predictors of the two subgroups we have described are two TNF receptors, (soluble TNFR1, TNFR2) and the soluble alpha-subunit of the IL-2 receptor, IL2RA. sTNFR1/2 are thought to regulate inflammatory signalling by TNF-α by competing with membrane-associated TNF receptors for TNF-α [44]. It has been previously argued that receptors such as sTNFR1 may be a better indicator of the TNF-α system activity than TNF-α itself due to difficulties in the reliable measurement of TNF-α [45–47]. sIL-2RA is used as a marker of T-cell activation and is increased in several cancers and in multiple sclerosis [48, 49]. The clusters also differentiated strongly on levels of sCD93 and suPAR. CD93 is expressed on microglia and is involved in central nervous system (CNS) inflammation [25, 50, 51]. However, the degree to which peripheral CD93 reflects CNS inflammation has not yet been determined. suPAR has been identified as a predictor of chronic diseases [52], disease severity and mortality [53, 54] and is thus regarded as a measure of chronic inflammation [22, 23]. Elevated levels of TNFRI/2, CD93 and suPAR levels may reflect a unique pattern of inflammation that is particularly relevant to a subgroup of individuals with psychiatric disorders.

The subgroups we identified are of potential transdiagnostic clinical significance. In this study, the subgroup with higher levels of inflammatory markers had a greater proportion of individuals who had psychotic experiences in the past year and a greater proportion of individuals who were not in employment, education or training, the latter finding being the strongest. Social and role functioning are increasingly recognised as important outcomes [55–59], and psychiatric disorders have been associated with future long-term exclusion from education, employment or

| Table 2. Difference in cluster inflammatory marker means, 95% CI. |
|-----------------|----------------|----------------|
| Difference in means | 95% CI |   |
| IFN-γ           | 0.26 | 0.07 | 0.46 |
| IL-10           | 0.29 | 0.08 | 0.50 |
| IL-6RA          | 0.30 | 0.11 | 0.50 |
| IL-8            | 0.35 | 0.15 | 0.56 |
| A2M             | 0.40 | 0.20 | 0.59 |
| IL-6            | 0.44 | 0.25 | 0.63 |
| sVCAM-1         | 0.52 | 0.32 | 0.72 |
| IL-1RT2         | 0.55 | 0.35 | 0.75 |
| TNF-α           | 0.58 | 0.38 | 0.79 |
| CRP             | 0.60 | 0.40 | 0.81 |
| IL-1RT1         | 0.74 | 0.55 | 0.93 |
| sICAM-1         | 0.79 | 0.59 | 0.99 |
| IL-2RA          | 1.01 | 0.84 | 1.18 |
| CD93            | 1.03 | 0.86 | 1.20 |
| suPAR           | 1.15 | 0.96 | 1.34 |
| TNFR1           | 1.31 | 1.15 | 1.48 |
| TNFR2           | 1.47 | 1.32 | 1.62 |

Difference in means of normalised inflammatory markers between cluster 1 and cluster 2 are presented using cluster 1 as the reference group.

| Table 3. Characteristics of the transdiagnostic clusters. |
|-----------------|----------------|----------------|
|                  | Cluster 1 (n = 217) | Cluster 2 (n = 163) | P value |
| Psychotic disorder, n (%) | 18 (8.3%) | 22 (13.5%) | 0.143 |
| Depressive disorder, n (%) | 113 (52.1%) | 89 (54.6%) | 0.700 |
| Generalised anxiety disorder, n (%) | 157 (72.4%) | 111 (68.1%) | 0.432 |
| Sex               | Male, n (%) | Female, n (%) |   |
|                  | 58 (26.7%) | 159 (73.3%) |   |
|                  | 39 (23.9%) | 124 (76.1%) |   |
| BMI, mean (SD)    | 24.6 (4.9) | 26.3 (7.0) | 0.049 |
| Daily smoker, n (%) | 35 (16.1%) | 45 (27.6%) | 0.007 |
| Major physical health condition, n (%) | 5 (2.3%) | <5 (<3.1%) | 0.924 |
| Number of nights with sleep problems in past 7 nights, n (%) | 1–3 | 76 (35.0%) | 4–7 | 67 (30.9%) |
|                  | 62 (38.0%) | 44 (27.0%) |   |
| Has received medication for hallucinations/delusions or other mental health problem, n (%) | 39 (18.0%) | 42 (25.8%) | 0.087 |
| Suspected or definite psychotic experiences within the past year, n (%) | 34 (15.7%) | 44 (27.0%) | 0.010 |
| Anhedonia within the past month | Less enjoyment than usual, n (%) | 144 (66.4%) | 98 (60.1%) | 0.106 |
|                  | Did not enjoy anything, n (%) | 8 (3.7%) | 14 (8.6%) |   |
| Not in employment, education or training | 18 (8.3%) | 35 (21.5%) | <0.001 |

*Data suppressed due to small cell counts.
training while adjusting for sociodemographic confounders [60]. In line with this, it has previously been highlighted that those with psychotic experiences represent the more severe end of a continuum of ‘common mental distress’ [61]. Our results indicate the subgroups we identified are relevant to potential transdiagnostic measures of illness impairment or severity; NEET status and the presence of psychotic experiences. The subgroup with higher levels of inflammatory markers also had a greater proportion of individuals who were daily smokers. As tobacco smoking can increase peripheral inflammatory marker levels [62, 63], we conducted an additional analysis including daily smoking additional binary covariate. Including the smoking covariate had little effect on our results, suggesting that the inflammatory subgroups were not confounded by smoking status. Furthermore, there was no evidence that the clusters differed in the proportions of individuals with major physical health conditions or sleep problems.

The methods we applied and the cross-sectional nature of the data in this study do not allow us to infer causality. While we were able to adjust for confounders such as sex, BMI and smoking (additionally, participants were all of a similar age), the clustering solutions we have described could reflect differences in lifestyle factors such as diet and physical activity, as well as differences in socio-economic status [62, 63]. Alternatively, the clusters could reflect a subgroup of individuals with long-standing chronic inflammation (as indicated by higher levels of suPAR [22, 23]) that is associated with their poorer role functioning (as indicated by the higher proportions of NEET status in cluster 2).

The subgroups we identified differed most prominently in levels of soluble TNF-α receptor 1 and 2. A previous randomised-controlled trial (RCT) in individuals with treatment-resistant depression investigated the efficacy of infliximab, a monoclonal antibody for TNF-α, in the reduction of depressive symptoms [64]. No overall effect of infliximab over placebo was found, although a significant interaction between treatment, time and baseline CRP concentration with reduction in depressive symptom score was found. There was no such interaction between treatment, time and baseline levels of sTNFR1/2. A separate RCT of adjunctive infliximab in bipolar depression also reported absence of a sustained main effect of infliximab over placebo on anhedonia. However, the authors reported an interaction between treatment, time and baseline STNFR1 with reduction in anhedonia [65]. In the present study, subgroup membership was not solely based on levels of sTNFR1/2, with circulating levels of suPAR, IL-2R and CD93 also differentiating strongly between the subgroups. These five markers together may confer additional information beyond sTNFR1/2 alone and could be used in the design of targeted trials of infliximab, other immune-regulating therapeutics, or exercise-based interventions [66, 67] for individuals with psychiatric disorders.

Recently there have been alternative approaches to ensuring specificity of clustering solutions to psychiatric populations. A previous study found evidence for a subgroup of patients with schizophrenia and bipolar disorder positive for the human endogenous retrovirus type W (HERV-W) envelope protein that exhibit increased levels of IL-6 and IL-1β [68]. In this case, the addition of the HERV-W biomarker aided in the identification of inflammatory subgroups specific to the psychotic disorders. A recent study by Luo et al. [69] clustered schizophrenia patients by their epigenetic profile and identified two subgroups that differed in leucocyte cell counts and neuroanatomical features. Similar subgroups were found when repeating the clustering with controls only, however, the control subgroups did not show neuroanatomical differences, demonstrating specificity of the patient clusters to schizophrenia.

This study has a number of strengths and limitations. Firstly, this study benefitted from a large subsample of a well-characterised general population cohort. However, the ALSPAC sample is subject to attrition, which may affect the generalisability of these results. Attrition in ALSPAC differs along the socioeconomic gradient and there may be individuals with lower levels of functioning that have not been represented in this study. In our study, 30% of participants with one psychiatric disorder also met criteria for another psychiatric disorder, supporting the transdiagnostic approach to our research question. However, while we were able to include large numbers of individuals with depressive disorder and GAD, our study included relatively few individuals with psychotic disorder (n = 40) which limits the applicability of our results to psychotic disorder alone. Furthermore, there are no specific guidelines currently available for sample size requirements of the clustering method used, and our study would have benefitted from an even larger sample. The lack of an external validation sample is also a limitation of this study. Our analysis should be repeated in another sample to investigate whether the clustering solutions are reproducible.

The extent to which cytokines can be measured reliably with multiplex immunoassays varies considerably [70]. While some inflammatory markers, such as IL-1β and IL-2, did not pass our quality control, we were able to include a wide range of peripheral biomarkers in our analyses as well as receptors for IL-1β and IL-2. Our findings that inflammatory marker receptors may be superior predictors of inflammatory subtypes in psychiatric disorders may simply be a reflection of the differences in sensitivity between the two methods used: multiplex ELISA and PEA. Finally, the measures of anhedonia and role functioning in this study were relatively crude. Continuous measures of the severity of anhedonia and role functioning (capturing the amount of support needed in the current role) may have been more informative.

To investigate the existence of inflammatory subgroups specific to psychiatric disorders, we have used a method that has three clear advantages: (i) controls are used as a reference population, (ii) covariate adjustment is possible, and (iii) the stability of clusters can be assessed through internal validation techniques as an initial measure of their potential reproducibility. The algorithm HYDRA has previously been evaluated on genetic data [21] and has indicated the existence of two neuroanatomical clusters of schizophrenia using structural MRI data [41, 71, 72]. Here, we have applied the algorithm to peripheral inflammatory marker data, allowing us to consider the relevance of the clustering solutions to psychiatric disorders in light of data from controls, and adjust for the confounders sex and BMI [62]. We believe the subgroups we have identified will have better chances of being reproducible and applicable due to the advantages of the methods we have applied. However, it should be acknowledged that our modelling strategy makes the assumption that there are inflammatory subgroups specific to individuals with psychiatric disorders. In an alternative model, one could assume that there are inflammatory subgroups among the general population, with certain subgroups having greater risk of psychiatric disorder or symptoms. Nevertheless, the present study provides evidence for the former model.

In conclusion, this study found evidence for the presence of two transdiagnostic inflammatory subgroups of individuals with psychiatric disorders, which showed differences in their role functioning. These findings may be particularly useful in the identification of subgroups that could be targeted in clinical trials of anti-inflammatory therapeutics or interventions. We aim to replicate our results in future studies using a reduced panel of inflammatory biomarkers.

**CODE AVAILABILITY**

The code used to generate the results in this study are available upon reasonable request from the corresponding author.

**J.F. Byrne et al.**
REFERENCES

1. Fragunas DJ, Diaz-Caneda CM, Ayora M, Hernández-Alvarez F, Rodríguez-Quiraga A, Recio S, et al. Oxidative stress and inflammation in first-episode psychosis: a systematic review and meta-analysis. Schizophr Bull. 2019;45:742–51.

2. Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand. 2017;135:373–87.

3. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 10, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 2015;49:206–15.

4. Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naïve first episode psychosis: A systematic review and meta-analysis. Schizophr Res. 2015;161:156–65.

5. Costello H, Gould RL, Abrol E, Howard R. Inflammation and anxiety disorders in major depression. BMJ Open. 2019;9:e027925.

6. Căciuc N, van Beveren NM, Judge-Hundal G, Koola MM, Sommer IEC. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med. 2019;49:2307–19.

7. Bai S, Guo W, Peng Y, Deng H, Li G, Nie H, et al. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2020;91:21–32.

8. Ai-Diwani A, Pillinger T, Lennox B. Immunosuppressivity in 2022: premise to promise, and back again. Lancet Psychiatry. 2022;9:11–2.

9. Ioannou M, Foxeille M, Jeelani J, Starn EL, Bodin O, Dubertret C, et al. Towards precision medicine: what are the stratification hypotheses to identify homogeneous inflammatory subgroups. Eur Neuropsychopharmacol. 2021;45:108–21.

10. Koppe G, Meyer-Lindenberg A, Durstewitz D. Deep learning for small and big data in psychiatry. Neuropsychopharmacology. 2021;46:176–90.

11. Tamminga CA, Clementz BA. Biological fingerprints for psychosis. Neurpsychopharmacology. 2020;45:235-.

12. Oismo EF, Pillinger T, Rodríguez IG, Khamdaker GM, Pariante CM, Howes OD. Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun. 2020;87:901–9.

13. Pillinger T, Oismo EF, Brugger S, Mondelli V, McCutcheon RA, Howes OD. A meta-analysis of immune parameters, variability, and assessment of modal distribution in psychosis and test of the immune subgroup hypothesis. Schizophr Bull. 2019;45:1120–33.

14. Boerrigter D, Weickert TW, Lenroot R, O'Donnell M, Galletly C, Liu D, et al. Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schaafatoressive disorder. J Neuroinflammation. 2017;14:188.

15. Lizano P, Lutz O, Xu Y, Rubin LH, Paskowitz L, Lee AM, et al. Multivariate relations between peripheral inflammatory marker subtypes and cognitive and brain structural measures in psychosis. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-00914-0.

16. North HF, Weissleder C, Vollert JM, Sager R, Webster MJ, Weickert CS. Schizophrenia. In: North HF, Weissleder C, Vollert JM, Sager R, Webster MJ, Weickert CS, editors. Schizophrenia: what are the stratification hypotheses to identify homogeneous inflammatory subgroups. Eur Neuropsychopharmacol. 2021;45:108–21.

17. Haroon E, Welle JR, Woolwine BJ, Goldsmith DR, Baer W, Patel T, et al. Associations between estimated suPAR, a new biomarker of inflammation, and accelerated aging. J Gerontol Ser A. 2021;76:318–27.

18. Bourassa KJ, Rasmussen LJ, Danese A, Eugen-Olsen J, Harrington H, Houts R, et al. Linking stressful life events and chronic inflammation using suPAR (soluble urokinase plasminogen activator receptor). Brain Behav Immun. 2021;97:79–88.

19. Föcking M, Sabherwal S, Cates HM, Scaife C, Dicker P, Hryniewiecka M, et al. Complement system biomarkers in first episode psychosis. Schizophr Res. 2019;204:16–22.

20. Mengon D, Healy C, Jones HJ, Zammit S, Cannon M, Cotter DR. Plasma polyunsaturated fatty acids and mental disorders in adolescence and early adulthood: cross-sectional and longitudinal associations in a general population cohort. Transl Psychiatry. 2021;11:321.

21. Northstone K, Lewcock M, Groom A, Boyd A, Macleod J, Timpson NJ, et al. The Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled sample of index children in 2019. Wellcome Open Res. 2019;4:377–81.

22. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81.

23. Horwood J, Salvi G, Thomas K, Duffy L, Gunnell D, Hollis C, et al. IQ and non-clinical psychotic symptoms in 12-year-olds: results from the ALSPAC birth cohort. Br J Psychiatry. 2008;193:185–91.

24. Zammit S, Kounali D, Cannon M, David AS, Gunnell D, Heron J, et al. Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study. Am J Psychiatry. 2013;170:472–50.

25. Patton GC, Coffey C, Fosterino M, Carlin JB, Wolfe R, Bowes G. A computerised screening instrument for adolescent depression: population-based validation and application to a two-phase case-control study. Soc Psychiatry Psychiatr Epidemiol. 1999;34:166–72.

26. Mengon D, Healy C, Jones HJ, Zammit S, Cannon M, Cotter DR. Plasma polyunsaturated fatty acids and mental disorders in adolescence and early adulthood: cross-sectional and longitudinal associations in a general population cohort. Transl Psychiatry. 2021;11:321.

27. World Health Organization. Schedules for clinical assessment in neuropsychiatry: version 2. (American Psychiatric Press, 1994).

28. Sullivan SA, Kounali D, Cannon M, David AS, Fletcher PC, Holmans P, et al. A population-based cohort study examining the incidence and impact of psychotic experiences from childhood to adulthood, and prediction of psychotic disorder. AJP. 2020;177:308–17.

29. World Health Organization. The international statistical classification of diseases and health related problems ICD-10: tenth revision, 2nd ed. (World Health Organisation, 2004).

30. Kouta M, Leung KL, Fuglsang F, Hultman C, Hultenby K, et al. Complement system biomarkers in first episode psychosis. Schizophr Res. 2019;204:16–22.

31. Liu Y, Hayes DN, Nobel A, Marron J.S. Statistical significance of clustering for high-dimension low–sample size data. Null. 2008;103:1281–93.

32. Lalousis PA, Wood SJ, Schmaal L, Chisholm K, Griffiths SL, Remien RE, et al. Heterogeneity and classification of recent onset psychosis and depression: a multimodal machine learning approach. Schizophr Bull. 2021. https://doi.org/10.1093/schbul/sbaa185.

33. Frank P, Jokela M, Batty GD, Cadar D, Steptoe A, Kivimäki M. Association between inflammation and individual symptoms of depression: a pooled analysis of 15 population-based cohort studies. AJP. 2021;178:107–18.

34. Kopczyńska M, Zelek W, Tan A, S. Gaughan F, Di Foro M, Mondelli V, et al. Complement system biomarkers in first episode psychosis. Schizophr Res. 2019;204:16–22.

35. Adams E, Gaultney JF, Byerly S, Burke R, Wallach D. Stabilization of the biocompatibility of tumor necrosis factor b its soluble receptors. J Exp Med. 1992;175:323–9.

36. Bergin DA, Reeves EP, Hurley K, Wolfe R, Jameel R, Fitzgerald S, et al. The circulating proteinase inhibitor α-1 antitrypsin regulates neutrophil degranulation and autoimmunity. Sci Transl Med 2014;6:217ra1–217ra1.

37. Brunsgaard H. Physical activity and modulation of systemic low-level inflammation. J Leukoc Biol. 2005;78:819–35.
8

J.F. Byrne et al.

47. Zhou X, Fragala MS, McElhaney JE, Kuchel GA. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. Curr Opin Clin Nutr Metab Care. 2010;13:541–7.

48. Lokau J, Garbers C. Biological functions and therapeutic opportunities of soluble cytokine receptors. Cytokine Growth Factor Rev. 2020;55:94–108.

49. Maier LM, Anderson DE, Severson CA, Baeker-Allan C, Healy B, Liu DV, et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol. 2009;182:1541.

50. Webster SD, Park M, Fonseca MI, Tenner AJ. Structural and functional evidence for microglial expression of C1qR(P), the C1q receptor that enhances phagocytosis. J Leukoc Biol. 2000;67:109–16.

51. Liu C, Cui Z, Wang S, Zhang D. CD93 and GIPC expression and localization during cerebellar system inflammation. Neural Regen Res. 2016;11:995–2011.

52. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predictor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268:296–308.

53. Enossson H, Wetterö J, Skogh T, Sköwal C. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. Transfus Res. 2013;162:287–96.

54. Rasmussen LH, Ladelund S, Haupt TH, Ellekilde G, Poulsen JH, Iversen K, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J. 2016;33:769.

55. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McElhaney JE, Kuchel GA. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. J Affect Disord. 2021;280:267–76.

56. Webster SD, Park M, Fonseca MI, Tenner AJ. Structural and functional evidence for microglial expression of C1qR(P), the C1q receptor that enhances phagocytosis. J Leukoc Biol. 2000;67:109–16.

57. Zhou X, Fragala MS, McElhaney JE, Kuchel GA. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. Curr Opin Clin Nutr Metab Care. 2010;13:541–7.

58. Fond G, Faugere M, Richieri R, Cermolacce M, Korchia T, Micoulaud-Franchi J, et al. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. Transfus Res. 2013;162:287–96.

59. Rasmussen LH, Ladelund S, Haupt TH, Ellekilde G, Poulsen JH, Iversen K, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J. 2016;33:769.

60. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McElhaney JE, Kuchel GA. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. J Affect Disord. 2021;280:267–76.

61. Liu C, Cui Z, Wang S, Zhang D. CD93 and GIPC expression and localization during cerebellar system inflammation. Neural Regen Res. 2016;11:995–2011.

62. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predictor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268:296–308.

63. Enossson H, Wetterö J, Skogh T, Sköwal C. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. Transfus Res. 2013;162:287–96.

64. Rasmussen LH, Ladelund S, Haupt TH, Ellekilde G, Poulsen JH, Iversen K, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J. 2016;33:769.

65. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McElhaney JE, Kuchel GA. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. J Affect Disord. 2021;280:267–76.

66. Webster SD, Park M, Fonseca MI, Tenner AJ. Structural and functional evidence for microglial expression of C1qR(P), the C1q receptor that enhances phagocytosis. J Leukoc Biol. 2000;67:109–16.

67. Zhou X, Fragala MS, McElhaney JE, Kuchel GA. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. Curr Opin Clin Nutr Metab Care. 2010;13:541–7.

68. Lokau J, Garbers C. Biological functions and therapeutic opportunities of soluble cytokine receptors. Cytokine Growth Factor Rev. 2020;55:94–108.

69. Maier LM, Anderson DE, Severson CA, Baeker-Allan C, Healy B, Liu DV, et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol. 2009;182:1541.

70. Webster SD, Park M, Fonseca MI, Tenner AJ. Structural and functional evidence for microglial expression of C1qR(P), the C1q receptor that enhances phagocytosis. J Leukoc Biol. 2000;67:109–16.

71. Chand GB, Dwyer DB, Erus G, Sotiras A, Varol E, Sinivasan D, et al. Two distinct neuroanatomical subtypes of schizophrenia revealed using machine learning. Brain. 2020;141:1027–38.

72. Wen J, Varol E, Sotiras A, Yang Z, Chand GB, Erus G, et al. Multi-scale semi-supervised clustering of brain images: deriving disease subtypes. Med Image Anal. 2022;75:102304.

ACKNOWLEDGEMENTS

We are extremely grateful to all the families who took part in the ALSPAC study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. We would like to thank Dr. John Butler for his assistance with the multiplex ELISA. We would also like to thank Dr. Pariss Alexandros Laloussis and Dr. Junhao Wen for their advice on HYDRA and Eoghan Cunningham for his critical review of the data analysis and manuscript.

AUTHOR CONTRIBUTIONS

JFB, CH and DRC were responsible for the conception and design of the work. SRS, MF and DM carried out the acquisition of inflammatory biomarker data. SZ obtained funding and for and coordinated the acquisition of the PLUKsi data. DM and JFB carried out the data extraction. JFB carried out the data analysis with support from CH, DM and DRC. DRC and MC contributed to the interpretation of the clinical findings. JFB drafted the manuscript. All authors critically revised the manuscript for important intellectual content and approved the submitted manuscript.

FUNDING

The UK Medical Research Council and Wellcome (Grant ref: 217065/2/19/2) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and Jonah Byrne will serve as the guarantor for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website. The collection of the outcomes used in this study was specifically funded by the Medical Research Council, including grant numbers MR/L022206/1 and MR/M006727/1. DRC, MF and JFB are supported by a Wellcome Flagship Innovations Award (MPETUS - 220438/Z/20/Z). DRC is supported by a Health Research Board Investigator Led Project Grant (ILP-POR-2017-039). MC is supported by a European Research Council Consolidator Award (IERH-748209). CH is supported by Health Research Board Investigator Led Project Grant (ILP-PHR-2019-009). DM is a Fellow on the Irish Clinical Academic Training (ICAT) Programme which is supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z), the Health Service Executive National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland. SRS is supported by the Health Research Board (HRB) under grant number HRB/ HRA/PHR/12-193. DRC, SRS and JFB are supported by Science Foundation Ireland (SFI) under Grant Number 16/RC/3948 and co-funded under the European Regional Development Fund and by FutureNeuro industry partners. SZ is supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol.

COMPETING INTERESTS

DM, MC and DRC report a patent pending (UK Patent Application No. 191155.0, “Biomarkers to predict psychosis”). CH, MF, SRS and JFB report no financial relationships with commercial interests.

ETHICAL APPROVAL AND CONSENT

Approval for ALSPAC was obtained from ALSPAC Ethics and Law Committee and local research ethics committees. Consent for biological samples was collected in accordance with the Human Tissue Act (2004). Written informed consent for the use of questionnaire and clinic data was obtained from all subjects following recommendations of the ALSPAC Ethics and Law Committee at the time. Ethical approval for the analysis of inflammatory biomarker levels was granted by the Royal College of Surgeons in Ireland (REC1240bb). The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

73. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McElhaney JE, Kuchel GA. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. Curr Opin Clin Nutr Metab Care. 2010;13:541–7.
ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41398-022-02142-2.

Correspondence and requests for materials should be addressed to Jonah F. Byrne.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022